ORGANOGENESIS HOLDINGS INC. Variable Lease, Cost
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Variable Lease, Cost of $8.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. variable lease, cost for the quarter ending 2024-06-30 was $903.00K, a 42.70% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. variable lease, cost for the quarter ending 2024-03-31 was $1.13M, a 37.24% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. variable lease, cost for the quarter ending 2023-12-31 was $728.00K, a 52.04% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. variable lease, cost for the quarter ending 2023-09-30 was $1.50M, a 9.83% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. variable lease, cost for fiscal 2025 was $8.39M, a 26.79% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. variable lease, cost for fiscal 2024 was $6.62M, a 18.23% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. variable lease, cost for fiscal 2023 was $5.59M, a 10.09% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. variable lease, cost for fiscal 2022 was $5.08M, a 5.70% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $8.39M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $6.62M 10-K · filed 2026-02-26 | |||
| 2024-06-30 | $903.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.03M 10-Q · filed 2024-08-08 | $2.76M derived: sum of 3 quarters · filed 2026-02-26 | $4.25M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.13M 10-Q · filed 2024-05-09 | $1.85M derived: sum of 2 quarters · filed 2026-02-26 | $3.35M derived: sum of 3 quarters · filed 2026-02-26 | $4.93M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $728.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.23M derived: sum of 2 quarters · filed 2026-02-26 | $3.80M derived: sum of 3 quarters · filed 2026-02-26 | $5.59M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.07M derived: sum of 2 quarters · filed 2024-08-08 | $4.87M 10-Q · filed 2023-11-09 | $6.38M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-06-30 | $1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.37M 10-Q · filed 2024-08-08 | $4.89M derived: sum of 3 quarters · filed 2024-08-08 | $6.25M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.79M 10-Q · filed 2024-05-09 | $3.31M derived: sum of 2 quarters · filed 2024-05-09 | $4.67M derived: sum of 3 quarters · filed 2024-05-09 | $5.96M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.88M derived: sum of 2 quarters · filed 2024-02-29 | $4.16M derived: sum of 3 quarters · filed 2024-02-29 | $5.08M 10-K · filed 2024-02-29 |
| 2022-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.65M derived: sum of 2 quarters · filed 2023-11-09 | $3.56M 10-Q · filed 2023-11-09 | $4.62M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $2.20M 10-Q · filed 2023-08-09 | $3.26M derived: sum of 3 quarters · filed 2023-08-09 | $4.56M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $918.00K 10-Q · filed 2023-05-10 | $1.97M derived: sum of 2 quarters · filed 2023-05-10 | $3.28M derived: sum of 3 quarters · filed 2023-05-10 | $4.36M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.36M derived: sum of 2 quarters · filed 2023-03-01 | $3.44M derived: sum of 3 quarters · filed 2023-03-01 | $4.81M 10-K · filed 2023-03-01 |
| 2021-09-30 | $1.30M 10-Q · filed 2021-11-09 | $2.39M derived: sum of 2 quarters · filed 2021-11-09 | $3.75M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.09M 10-Q · filed 2021-08-09 | $2.45M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $1.36M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |